Rapport Therapeutics Inc (NASDAQ:RAPP)’s traded shares stood at 60888.0 during the last session, with the company’s beta value hitting 0.40. At the close of trading, the stock’s price was $12.04, to imply an increase of 2.03% or $0.24 in intraday trading. The RAPP share’s 52-week high remains $29.74, putting it -147.01% down since that peak but still an impressive 46.59% since price per share fell to its 52-week low of $6.43. The company has a valuation of $439.43M, with an average of 0.15 million shares in intraday trading volume over the past 10 days and average of 181.09K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Rapport Therapeutics Inc (RAPP), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give RAPP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy.
Rapport Therapeutics Inc (NASDAQ:RAPP) trade information
After registering a 2.03% upside in the last session, Rapport Therapeutics Inc (RAPP) has traded red over the past five days. The 5-day price performance for the stock is 1.95%, and -1.63% over 30 days. With these gigs, the year-to-date price performance is -52.67%. Short interest in Rapport Therapeutics Inc (NASDAQ:RAPP) saw shorts transact 2.83 million shares and set a 12.77 days time to cover.
The extremes give us $35 and $35 for target low and target high price respectively. As such, RAPP has been trading -190.7% off suggested target high and -190.7% from its likely low.
RAPP Dividends
Rapport Therapeutics Inc has its next earnings report out on 2025-May-08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Rapport Therapeutics Inc (NASDAQ:RAPP)’s Major holders
Rapport Therapeutics Inc insiders hold 6.40% of total outstanding shares, with institutional holders owning 105.23% of the shares at 112.43% float percentage. In total, 105.23% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 4.98 million shares (or 13.6245% of shares), all amounting to roughly $115.91 million.
The next major institution holding the largest number of shares is ARCH VENTURE MANAGEMENT, LLC with 3.73 million shares, or about 10.1944% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $86.73 million.
We also have SMALLCAP WORLD FUND INC and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund as the top two Mutual Funds with the largest holdings of the Rapport Therapeutics Inc (RAPP) shares. Going by data provided on Mar 31, 2025, SMALLCAP WORLD FUND INC holds roughly 2.6 shares. This is just over 7.13% of the total shares, with a market valuation of $31.33 million. Data from the same date shows that the other fund manager holds a little less at 1.54, or 4.23% of the shares, all valued at about 18.58 million.
